Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

93 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-01-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Iron overload impaired growth in Thalassemia patients due to iron deposition in the endocrine glands, including the hypophysis and gonads. The issue of iron overload in Sickle Cell Anemia is recently studied more extensively and preliminary studies shows that endocrine damage is rarer in those patients.

Growth velocity was not systematically studied in patients with Iron Overload, even in thalassemia patients in spite several studies that assess the endocrine function in those patients. In Sickle Cell Patients this issue was not studied.

The purpose of this study is to assess the growth velocity in a cohort of Thalassemia Major and Intermedia patients and compare the results to another group of Sickle Cell patients, including Sickle cell thalassemia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia

NCT00512564

Sickle Cell Anemia Sickle Cell Thalassemia

COMPLETED

Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia

NCT00512226

Sickle Cell Anemia Sickle Cell Thalassemia Iron Overload +1 more

COMPLETED NA

The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia

NCT00971698

Sickle Cell Anemia Thalassemia

COMPLETED

Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects

NCT00971880

Thalassemia Sickle Cell Anemia

COMPLETED

Detection of β Thalassemia Carriers by Red Cell Parameters Obtained From the H2 Automatic Counter

NCT00481221

Thalassemia Iron Deficiency

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Growth velocity, endocrine function and iron overload status will be studied in the patients that are in follow up at the Pediatric Hematology Unit, at the Ha'Emek Medical Center.

Patients who were lost from follow up or insufficient data about growth in the past will not included in the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thalassemia Sickle Cell Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Thalassemia Group

Patients suffering from Thalassemia Major and patients with Thalassemia Intermedia

Medical Chart Summary

Intervention Type OTHER

Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.

Sickle Cell Group

Patients with Sickle Cell Anemia and Sickle Cell Thalassemia

Medical Chart Summary

Intervention Type OTHER

Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medical Chart Summary

Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients in follow up with available medical charts.

Exclusion Criteria

* Patients lost from follow up or without enough data to calculate growth velocity or clinical and laboratory endocrine assessment or missing data about iron status.

Minimum Eligible Age

5 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No